This site is intended for health professionals only

Published on 22 November 2011

Share this story:
Twitter
LinkedIn

Schizophrenia substance set for FDA review

teaser

The US Food and Drug Administration (FDA) has determined that a new drug application (NDA) for Otsuka’s investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.

Otsuka and Lundbeck entered into a long-term CNS agreement for up to five innovative psychiatric and neuroscience products on 11 November 2011.

The two companies are collaborating on the co-development and co-commercialization (following approval of regulatory authorities) of aripiprazole depot formulation worldwide.

The NDA is based on data from a phase III clinical study designed to evaluate the efficacy, safety and tolerability of the intramuscular formulation as a maintenance treatment in patients with schizophrenia.

In October 2010, an independent data monitoring committee recommended the early termination of the Phase III, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

This was due to the study successfully meeting efficacy criteria at a protocol-specified interim analysis.

“Aripiprazole, a dopamine, D2 partial agonist with its unique pharmacological profile, has been prescribed around the world while recognized as an important long-term treatment option for patients with schizophrenia,” said Dr. Taro Iwamoto, President and Representative Director, Otsuka Pharmaceutical Co., Ltd.

“The submission of this NDA for the once monthly aripiprazole depot formulation is the first step in providing another treatment option for the current problems faced by patients with schizophrenia.”

Ulf Wiinberg, President & Chief Executive Officer at Lundbeck, added: “We are very pleased that our new partner, Otsuka, has submitted an NDA for the aripiprazole depot formulation as this will potentially provide patients suffering from schizophrenia in the US with a new treatment option.

“Schizophrenia is a serious disease and there is still a great need to offer patients improved maintenance therapies and for therapies that can improve compliance.”

FDA


Most read

3

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn